Terms: = Prostate cancer AND CgA AND Prognosis
42 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract] [Full Text] [Related]
4. Non-functional paraganglioma of urinary bladder managed by transurethral resection.
Zhang B; Fu Z; Liu L; Qiao B; Liu C
Int Braz J Urol; 2019; 45(5):910-915. PubMed ID: 31038858
[TBL] [Abstract] [Full Text] [Related]
5. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant prostate cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis.
Hong P; Guo RQ; Song G; Yang KW; Zhang L; Li XS; Zhang K; Zhou LQ
Asian J Androl; 2018; 20(6):561-566. PubMed ID: 30084431
[TBL] [Abstract] [Full Text] [Related]
7. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
[TBL] [Abstract] [Full Text] [Related]
8. Serum Chromogranin A as a Complementary Marker for the Prediction of prostate cancer-Specific Survival.
Niedworok C; Tschirdewahn S; Reis H; Lehmann N; Szücs M; Nyirády P; Romics I; Rübben H; Szarvas T
Pathol Oncol Res; 2017 Jul; 23(3):643-650. PubMed ID: 28012116
[TBL] [Abstract] [Full Text] [Related]
9. Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.
Brunello A; Fontana A; Zafferri V; Panza F; Fiduccia P; Basso U; Copetti M; Lonardi S; Roma A; Falci C; Monfardini S; Cella A; Pilotto A; Zagonel V
J Cancer Res Clin Oncol; 2016 May; 142(5):1069-77. PubMed ID: 26758276
[TBL] [Abstract] [Full Text] [Related]
10. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.
Conteduca V; Burgio SL; Menna C; Carretta E; Rossi L; Bianchi E; Masini C; Amadori D; De Giorgi U
Prostate; 2014 Dec; 74(16):1691-6. PubMed ID: 25262981
[TBL] [Abstract] [Full Text] [Related]
11. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
[TBL] [Abstract] [Full Text] [Related]
12. [Paraganglioma of the prostate: a case report and review of the literature].
Chen J; Quan CY; Jiang N; Niu YJ
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):715-8. PubMed ID: 22934517
[TBL] [Abstract] [Full Text] [Related]
13. The prognostic role of preoperative chromogranin A expression in prostate cancer after radical prostatectomy.
Masieri L; Lanciotti M; Gontero P; Marchioro G; Mantella A; Zaramella S; Minervini A; Lapini A; Carini M; Serni S
Arch Ital Urol Androl; 2012 Mar; 84(1):17-21. PubMed ID: 22649955
[TBL] [Abstract] [Full Text] [Related]
14. [Management of advanced prostate cancer in elderly patients].
Bompas E; Dedecker L
Bull Cancer; 2012 Jul; 99 Suppl 1():S21-9. PubMed ID: 22511114
[TBL] [Abstract] [Full Text] [Related]
15. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
[TBL] [Abstract] [Full Text] [Related]
16. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract] [Full Text] [Related]
17. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract] [Full Text] [Related]
19. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract] [Full Text] [Related]
20. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract] [Full Text] [Related]
[Next]
